Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CURx Pharma enters into license deal with Gilead Sciences
The company said that FTI, a combination of fosfomycin and tobramycin, is ready for Phase III clinical trials, having completed a Phase II trial in CF patients. FTI
The company said that FTI, a combination of fosfomycin and tobramycin, is ready for Phase III clinical trials, having completed a Phase II trial in CF patients. FTI
In conjunction with the licensing deal, BioMotiv has established Kodosil Bio which will develop all compounds resulting from the license. BioAtla president and CEO Jay Short said the
The expanded deal into multiple therapeutic areas has been expanded owing to Jubilant’s skill sets in several therapeutic areas. The collaboration has been expanded to use Jubilant’s drug
The trial is designed to evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD. Around 120 patients with Huntington’s disease
The company is seeking approval of oritavancin is for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus
The new patent, entitled ‘Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation’, provides the company with exclusive commercial rights in Europe initially through to 29 March 2024, with
The trial met its primary endpoint of showing an objective response rate among patients within six months of treatment. The objective response comprised of complete response (clinically significant
Pamlico has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections. Main aim of the deal is to develop a
The drug is the first and only therapy approved by the FDA, which demonstrates symptomatic benefit in patients with NOH. NOH is a rare, chronic and often debilitating
Under the deal, DKSH will be responsible for providing registration, importation, warehousing, physical distribution and collection services for Cheplapharm’s products Vesanoid (Tretinoin) and Rohypnol (Flunitrazepam) in Brunei, Hong